Gastroenterologists continue to struggle to maintain a work-life balance.

Published Date: 02 Mar 2023

According to a new report from Medscape, many gastroenterologists have found that happiness levels and work-life balance are not easily restored, despite the impact of COVID-19 in the office.

Read Full News

Latest News

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

Antifungal Therapy Eased IBD Activity, With Iliyan D. Iliev, PhD Iliyan D. Iliev, PhD

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Dupilumab Improves Esophageal Distensibility in EoE: REMODEL Trial Evan Dellon, MD, MPH

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Fertility Treatment in IBD: Insights From the WIsDoM Cohort Eugenia Shmidt, MD, Zoë Gottlieb, MD

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

Individualizing IBD Care Beyond the Bowel, With David T. Rubin, MD David Rubin, MD

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Latest News

SIBO Tied to Higher Bile Acid Synthesis in Patients With Chronic Diarrhea

Fluconazole was linked to improved Mayo and Harvey-Bradshaw scores; Iliev outlines the placebo-controlled trial needed next.

Evan Dellon, MD, MPH, discusses REMODEL data showing dupilumab widened the esophagus vs placebo, with the biggest gains in patients with narrower caliber.

Multilevel Intervention Improves CRC Screening, With Aasma Shaukat, MD, MPH

Eugenia Shmidt, MD, and Zoë Gottlieb, MD, discuss WIsDoM data showing 73% of women with IBD conceived with fertility treatment, most via embryo transfer.

David T. Rubin, MD, on the questions, screening tools, and system barriers standing between IBD care and the whole patient.

News All Time

Optimizing IBD Treatment and Sequencing, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

Jordan Axelrad, MD, MPH, discusses first-line IBD therapy selection, sequencing after failure, treat-to-target monitoring, and evaluating new agents

When IBD Symptoms Don't Match Inflammation, With Jordan Axelrad, MD, MPH Jordan Axelrad, MD, MPH

A gastroenterologist explains why IBD symptoms don't always signal a flare, the biomarkers used to confirm inflammation, and counseling patients through Crohn's disease.

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

ACG Guideline Sets 18 Preventive Care Recommendations for Cirrhosis

5 Gastroenterology Headlines You Missed in September 2026

5 Gastroenterology Headlines You Missed in September 2026

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Exocrine Pancreatic Insufficiency Estimated in 40% of Chronic Pancreatitis

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Tulisokibart Meets Phase 3 Endpoints in Ulcerative Colitis, First for Anti-TL1A Alex Hillenbrand

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Obefazimod Delivers Week 44 Remission in Refractory UC Patients Alex Hillenbrand

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

The HCPFive: Top News for Healthcare Providers from the Week of 06/21 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including phase 3 data, new clinical findings, and regulatory updates.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

When Abdominal Pain Is Actually a Food Allergy: A GI Workup Brian Lacy, MD, PhD

Brian Lacy, MD, PhD, of Mayo Clinic discussed the stepwise approach to diagnosing non-IgE mediated food hypersensitivity at EAC 2026.

First Half 2026 Recap: Gastroenterology Alex Hillenbrand

Review the biggest gastroenterology news from the first half of 2026, including FDA updates, IBD advances, and key clinical trials.

Recommended News For You

Genomic Newborn Screening Could Identify Childhood Cancer Predisposition

Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer

Proton Therapy Fails to Beat IMRT in Prostate Cancer

Brain MRI Surveillance Alone May Be Enough in SCLC

Long-Term Results Favor Acalabrutinib Combo in MCL

Reducing social media to an hour a day boosts young people's self-image.

FDA Expands Durvalumab Label to Operable Lung Cancer

Recommended Articles For You

Practical Applications in Hematology Across Clinical Settings 

Work Participation in Chronic Hematologic Disease: Clinical Insights and Practical Strategies 

Seeing the Difference: Using Ultrasound to Distinguish Fibroadenoma from Cancer 

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Can Prior Authorization Be Better With Artificial Intelligence?

2.

How a California Oncologist Making $850k Spends Money

3.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

4.

Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.

5.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

1.

Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself

2.

Uncovering the Mysteries of Breast Cancer: The Journey to a Cure

3.

Erythropoiesis Modulation in Chronic Anemia Management

4.

Comprehensive Concepts in Oncology in Clinical Decision-Making

5.

Precision Cancer Risk Mitigation Strategies

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

2.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

3.

Managing Supportive Care During Platelet Recovery

4.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

5.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot